PASADENA, Calif., Jan. 28, 2021 /PRNewswire/ -- SeqOnce Biosciences, Inc., announced today the launch of its new AzureSeq One-Step Universal RT-qPCR kit for the detection of the novel coronavirus SARS-CoV-2 N501Y variant. The AzureSeq One-Step Universal SARS-CoV-2 RT-qPCR N501Y kit uses a single-tube reaction targeting the N1 nucleocapsid gene, both alleles of S gene N501Y (A23063T), and includes RNaseP as a control. The assay uses common qPCR instruments with detection channels of FAM, HEX, Cy5, and ROX.
top of page
Search
Recent Posts
See AllBy: Steven Loeb Venture capital used to be a cottage industry, with very few investing in tomorrow's products and services. Oh, how times...
Matterworks, Inc., developers of the world's most powerful metabolomics platform, which accelerates the discovery, development, and...
Luna, the leading provider of in-home physical therapy, has teamed up with UCI Health, to expand access to patient care by providing...
bottom of page
Comments